AU2023404553A1 - Polypeptide inhibitor, and preparation method therefor and use thereof - Google Patents

Polypeptide inhibitor, and preparation method therefor and use thereof Download PDF

Info

Publication number
AU2023404553A1
AU2023404553A1 AU2023404553A AU2023404553A AU2023404553A1 AU 2023404553 A1 AU2023404553 A1 AU 2023404553A1 AU 2023404553 A AU2023404553 A AU 2023404553A AU 2023404553 A AU2023404553 A AU 2023404553A AU 2023404553 A1 AU2023404553 A1 AU 2023404553A1
Authority
AU
Australia
Prior art keywords
alkyl
amino acid
acid
amino
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023404553A
Other languages
English (en)
Inventor
Yun Chen
Bao CHENG
Jiaqiang Dong
Zhen Gong
Wensheng Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Publication of AU2023404553A1 publication Critical patent/AU2023404553A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2023404553A 2022-11-30 2023-11-30 Polypeptide inhibitor, and preparation method therefor and use thereof Pending AU2023404553A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
CN202211530438.1 2022-11-30
CN202211530438 2022-11-30
CN202310206299.5 2023-03-03
CN202310206299 2023-03-03
CN202310261818.8 2023-03-15
CN202310261818 2023-03-15
CN202310349519.X 2023-03-31
CN202310349519 2023-03-31
CN202311144489.5 2023-09-05
CN202311144489 2023-09-05
PCT/CN2023/135637 WO2024114762A1 (zh) 2022-11-30 2023-11-30 一种多肽抑制剂、其制备方法和应用

Publications (1)

Publication Number Publication Date
AU2023404553A1 true AU2023404553A1 (en) 2025-07-10

Family

ID=91323029

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023404553A Pending AU2023404553A1 (en) 2022-11-30 2023-11-30 Polypeptide inhibitor, and preparation method therefor and use thereof

Country Status (10)

Country Link
US (1) US20260193294A1 (cg-RX-API-DMAC7.html)
EP (1) EP4628499A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025540765A (cg-RX-API-DMAC7.html)
KR (1) KR20250111134A (cg-RX-API-DMAC7.html)
CN (1) CN120202212A (cg-RX-API-DMAC7.html)
AU (1) AU2023404553A1 (cg-RX-API-DMAC7.html)
IL (1) IL321139A (cg-RX-API-DMAC7.html)
MX (1) MX2025006152A (cg-RX-API-DMAC7.html)
TW (1) TW202440611A (cg-RX-API-DMAC7.html)
WO (1) WO2024114762A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242221A1 (zh) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 新型修饰侧链、其制备方法和应用
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026052109A1 (zh) * 2024-09-06 2026-03-12 上海翰森生物医药科技有限公司 一种多肽抑制剂的药物组合物及其用途
WO2026057052A1 (zh) * 2024-09-14 2026-03-19 深圳信立泰药业股份有限公司 一种il-23受体抑制剂及其制备方法和用途
WO2026138829A1 (zh) * 2024-12-23 2026-07-02 上海医药集团股份有限公司 多肽抑制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201810154WA (en) * 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP4021919A1 (en) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Pcsk9 antagonist compounds
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
MX2022008740A (es) * 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
SMT202500254T1 (it) * 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
AU2021383828A1 (en) * 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor

Also Published As

Publication number Publication date
IL321139A (en) 2025-07-01
JP2025540765A (ja) 2025-12-16
MX2025006152A (es) 2025-07-01
CN120202212A (zh) 2025-06-24
US20260193294A1 (en) 2026-07-09
TW202440611A (zh) 2024-10-16
WO2024114762A1 (zh) 2024-06-06
KR20250111134A (ko) 2025-07-22
EP4628499A1 (en) 2025-10-08

Similar Documents

Publication Publication Date Title
EP4628499A1 (en) Polypeptide inhibitor, and preparation method therefor and use thereof
JP7460541B2 (ja) アシネトバクター・バウマンニ(Acinetobacter baumannii)に対するペプチド大環状分子
CA2922607C (en) 1,2,4-oxadiazole derivatives as immunomodulators
KR100648578B1 (ko) α-케토아미드 다촉매활성의 프로테아제 억제제
CA3237911A1 (en) Method for producing n-alkyl amino acid and peptide including n-alkyl amino acid
CN101279955B (zh) 作为二肽肽激酶-iv抑制剂的n-取代硫吗啉衍生物及其医药用途
CA3135024A1 (en) Methods for synthesizing .beta.-homoamino acids
US7265146B2 (en) Integrin receptor inhibitors
JP7746628B1 (ja) Tnf受容体1活性を阻害するための環状ペプチド
CN115190762B (zh) 新的取代的磺酰脲和磺酰亚胺脲衍生物
JP2022515720A (ja) Il-17に特異的な二環式ペプチドリガンド
CN105658670A (zh) 肽-低聚尿素嵌合化合物及其使用方法
AU2022356942A1 (en) Tricyclic polypeptide conjugated drug and use thereof
JP2020500907A (ja) 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
EP0153720A2 (en) Spergualin-related compounds having a phenylene group, a process for their preparation and their use as medicaments
US11866518B2 (en) Bicyclic peptide ligands specific for TSLP
KR20220124742A (ko) 표적화된 스테로이드 화합물
AU2022328932A1 (en) Polypeptide drug conjugate having novel structure and application thereof
JP4927566B2 (ja) Par−2アゴニスト
JPH02131458A (ja) 新スパガリン関連化合物、その製造法及びその用途
KR20160111846A (ko) 흉선 기질 림프단백질 매개 신호전달을 제어하는 펩타이드 유도체 및 이를 포함하는 알러지 및 천식 질환 예방 및 치료용 약학 조성물
JP4842254B2 (ja) Par−2アゴニスト
JP2003518085A (ja) Cd45阻害剤
CN116082182A (zh) 秋水仙碱衍生物的制备方法及其用途
WO2026057052A1 (zh) 一种il-23受体抑制剂及其制备方法和用途